NEW YORK (GenomeWeb News) – Navigenics has reeled in $18 million in Series C financing from an investment round that included The Procter and Gamble Company, Kleiner Perkins Caufield and Byers, and Mohr Davidow Ventures.
The company plans to use the financing to continue researching ways genomics can be used in preventive health care and to "expand our clinical offerings into exciting new areas and lead the way in making personal genomics an integral part of employer-sponsored preventive health and wellness programs," Navigenics CEO and President Vance Vanier said today.